Acumen Pharmaceuticals, Inc.
ABOS
$2.72
$0.041.49%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 4.96% | 35.41% | -42.21% | 22.50% | -24.82% |
| Total Depreciation and Amortization | -4.26% | 0.00% | 4.44% | 2.27% | -2.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.11% | 5.19% | 40.36% | 19.00% | 20.43% |
| Change in Net Operating Assets | 142.61% | -211.97% | 185.23% | -189.55% | 120.17% |
| Cash from Operations | 37.37% | 4.22% | 6.71% | -25.38% | -10.65% |
| Capital Expenditure | -- | 100.00% | 88.61% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -35.20% | 5.25% | 33.80% | -3.02% | 392.77% |
| Cash from Investing | -35.20% | 5.27% | 34.14% | -3.28% | 392.77% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | 100.00% | -711.11% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -- | -- | 100.00% | -300.00% | 78.57% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -28.60% | 50.68% | 221.63% | -324.19% | 107.01% |